Will Rosellini

Rosellini is the President of CytoImmune Therapeutics, Inc, a clinical stage biotechnology company. Previously, Rosellini was the CEO of Perimeter Medical, Inc. (TSX:V "PINK") where he oversaw 2 510K clearances, an RTO and $30M in capital raised. Prior to that he was the CEO Nexeon Medsystems, Inc., ("OTC:QB, NXNN")a medical device manufacturing company that went public in 2017. Before that he founded, raised $16M across A/B rounds and led Lexington Technology Group, LLC, a database company commercializing an electronic health record database solution to an exit ("DSS" NYSE). Before that he founded Sarif Biomedical LLC, a stereotactic cancer microsurgery with IP spun-out of Medtronic and led company to an exit with Marathon Patent Group, Inc. ("MARA" NSDQ). He subsequently served on the Marathon board of directors and chaired the Audit committee. Rosellini completed 2 acquisitions to form Telemend Medical, Inc. a clinical engineering services company and led that company to an exit in 2016. Rosellini was also CEO at Microtransponder, an implantable neurostimulation developer with solutions for stroke rehabilitation. He is a former minor league pitcher with the Diamondbacks of the Arizona League, holds a JD, MBA, MS of Accounting, MS of Computational Biology, MS of Neuroscience and MS of Regulatory Science.